

Renuka Iyer

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8925548/renuka-iyer-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

35
papers

870
citations

15
h-index

29
g-index

38
ext. papers

1,186
ext. citations

4.8
avg. IF

4.19
L-index

#	Paper	IF	Citations
35	NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 563-573	7.3	207
34	Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4317-4345	2.2	112
33	Sorafenib: a clinical and pharmacologic review. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 1943-55	4	104
32	PD-1 and Foxp3 T cell reduction correlates with survival of HCC patients after sorafenib therapy. <i>JCI Insight</i> , 2016 , 1,	9.9	45
31	Ecuzumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review. <i>Journal of Gastrointestinal Oncology</i> , 2014 , 5, E30-3	2.8	38
30	Augmentation of IFN- γ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy. <i>JCI Insight</i> , 2019 , 4,	9.9	34
29	Quality of life and hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2014 , 5, 296-317	2.8	34
28	Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors. <i>Current Oncology Reports</i> , 2016 , 18, 7	6.3	28
27	A review of erlotinib--an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 311-20	4	28
26	Management of Typical and Atypical Pulmonary Carcinoids Based on Different Established Guidelines. <i>Cancers</i> , 2018 , 10,	6.6	28
25	Clinicopathological characteristics and outcomes of rare histologic subtypes of gallbladder cancer over two decades: A population-based study. <i>PLoS ONE</i> , 2018 , 13, e0198809	3.7	24
24	Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications. <i>Cancers</i> , 2019 , 11,	6.6	23
23	Combined hepatocholangiocarcinoma: case-series and review of literature. <i>International Journal of Gastrointestinal Cancer</i> , 2006 , 37, 27-34		20
22	Erlotinib and radiation therapy for elderly patients with esophageal cancer - clinical and correlative results from a prospective multicenter phase 2 trial. <i>Oncology</i> , 2013 , 85, 53-8	3.6	19
21	Immunomodulation in hepatocellular cancer. <i>Journal of Gastrointestinal Oncology</i> , 2018 , 9, 208-219	2.8	16
20	Ki67 score as a potential predictor in the selection of liver-directed therapies for metastatic neuroendocrine tumors: a single institutional experience. <i>Journal of Gastrointestinal Oncology</i> , 2016 , 7, 441-8	2.8	14
19	Molecular Targets in Biliary Carcinogenesis and Implications for Therapy. <i>Oncologist</i> , 2015 , 20, 742-51	5.7	13

18	Multidisciplinary Management of Patients with Unresectable Hepatocellular Carcinoma: A Critical Appraisal of Current Evidence. <i>Cancers</i> , 2019 , 11,	6.6	10
17	Endothelial progenitor cell number and ERK phosphorylation serve as predictive and prognostic biomarkers in advanced hepatocellular carcinoma patients treated with sorafenib. <i>Oncolmmunology</i> , 2016 , 5, e1226718	7.2	9
16	A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 80, 497-505	3.5	9
15	Exploring the role of survivin in neuroendocrine neoplasms. <i>Oncotarget</i> , 2020 , 11, 2246-2258	3.3	8
14	Role of Adjuvant Chemotherapy in Pulmonary Carcinoids: An NCDB Analysis. <i>Anticancer Research</i> , 2019 , 39, 6835-6842	2.3	8
13	Quality-of-life (QoL) as a predictive biomarker in patients with advanced pancreatic cancer (APC) receiving chemotherapy: results from a prospective multicenter phase 2 trial. <i>Journal of Gastrointestinal Oncology</i> , 2014 , 5, 433-9	2.8	7
12	Breast cancer resistance protein (BCRP) and excision repair cross complement-1 (ERCC1) expression in esophageal cancers and response to cisplatin and irinotecan based chemotherapy. <i>Journal of Gastrointestinal Oncology</i> , 2014 , 5, 253-8	2.8	6
11	Targeted therapy in gastrointestinal malignancies. <i>Journal of Carcinogenesis</i> , 2014 , 13, 4	1.9	5
10	Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2020 , 25, e1825-e1836	5.7	4
9	Gemcitabine and capecitabine for advanced biliary cancer. <i>Journal of Gastrointestinal Oncology</i> , 2017 , 8, 728-736	2.8	4
8	Sequencing Systemic Therapy Pathways for Advanced Hepatocellular Carcinoma: A Cost Effectiveness Analysis. <i>Liver Cancer</i> , 2020 , 9, 549-562	9.1	4
7	Woodchuck VEGF (wVEGF) characteristics: Model for angiogenesis and human hepatocellular carcinoma directed therapies. <i>Archives of Biochemistry and Biophysics</i> , 2019 , 661, 97-106	4.1	3
6	A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies. <i>Cancer</i> , 2018 , 124, 3890-3899	6.4	3
5	Interleukin-6 as a biomarker in patients with hepatobiliary cancers. <i>Journal of Gastrointestinal Oncology</i> , 2019 , 10, 537-545	2.8	2
4	A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients with advanced solid tumors. <i>International Journal of Cancer</i> , 2021 , 149, 2063-2074	7.5	1
3	Mutant - and -Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy.. <i>JCO Precision Oncology</i> , 2022 , 6, e2100309	3.6	0
2	Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair. <i>Communications Biology</i> , 2021 , 4, 862	6.7	0
1	Immunotherapy in hepatocellular cancer. <i>Advances in Cancer Research</i> , 2021 , 149, 295-320	5.9	

